Exercise of Options and Issue of Shares

("Ideagen," "the Company" or the "Group'')

Exercise of Options, Issue of Shares and Total Voting Rights

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, announces that it has allotted a total of 360,612 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of 355,000 options by several employees and the purchase of a further 5,612 partnership shares by employees through the Company's Share Incentive Plan.

Application has been made to the London Stock Exchange for the 360,612 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 1 March 2019.

On Admission, the total number of Ordinary Shares in issue will be 219,773,247 and the total number of voting rights will therefore be 219,773,247. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides IRM software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com